Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY opened at $5.58 on Wednesday. Bayer Aktiengesellschaft has a 52-week low of $5.49 and a 52-week high of $11.33. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The stock has a fifty day simple moving average of $7.44 and a two-hundred day simple moving average of $7.43.

Analysts Set New Price Targets

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.